Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease | Synapse
February 22, 2017Open Access
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease
Key Points
Key points are not available for this paper at this time.
Abstract
Twenty-four-week oltipraz treatment significantly reduced the liver fat content in patients with NAFLD. Clinicaltrials.gov (NCT01373554).